Rekomendasi Terapi Antibiotik pada Kolesistitis dan Kolangitis Akut

Oleh :

dr. Sonny Seputra, Sp.B, M.Ked.Klin, FINACS

Terapi antibiotik yang tepat merupakan salah satu manajemen yang sangat penting dalam penanganan pasien kolesistitis dan kolangitis akut. Pemberian terapi antibiotik yang tepat sangat penting karena mortalitas dari kolesistitis dan kolangitis akut masih tinggi. Angka kematian berturut-turut sesuai derajat keparahan infeksi traktus biliaris adalah sebesar 2,4% untuk derajat 1 atau ringan, 4,7% untuk derajat 2 atau sedang, dan 8,4% untuk derajat 3 atau berat dengan adanya disfungsi organ.[1,2]

Tujuan Terapi Antibiotik pada Kolesistitis dan Kolangitis Akut

Dalam pengobatan kolesistitis dan kolangitis akut, bagian penting dari manajemen terapi adalah mengontrol sumber infeksi, yaitu drainase bilier. Terapi antibiotik diberikan untuk mengeradikasi kuman sesuai dengan karakteristik bakteri, sehingga dapat membatasi respon sepsis sistemik dan peradangan lokal, serta mencegah infeksi pada lokasi pembedahan dan pembentukan abses intrahepatik.[12-14]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Gomi H, Solomkin JS, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16.
2. Gomi H, Takada T, et al. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24:310–8.
3. Gomi H, Solomkin JS, et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20:60–70.
4. Sung YK, Lee JK, et al. The Clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial‐resistant pathogens. Am J Gastroenterol. 2012;107:473–83.
5. Peirano G, van der Bij AK, et al. Molecular epidemiology over an 11‐year Period (2000 to 2010) of extended‐Spectrum β‐lactamase‐producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294–9.
6. Mazuski JE, Tessier JM, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra‐Abdominal Infection. Surgical infections. 2017;18:1–76.
7. Coccolini F, Sartelli M, et al. Antibiotic resistance pattern and clinical outcomes in acute cholecystitis: 567 consecutive worldwide patients in a prospective cohort study. Int J Surg. 2015;21:32–7.
8. Reuken PA, Torres D, et al. Risk factors for multi‐drug resistant pathogens and failure of empiric first‐line therapy in acute cholangitis. PLoS One. 2017;12:1–12.
9. Kwon JS, Han J, et al. Changes in causative pathogens of acute cholangitis and their antimicrobial susceptibility over a period of 6 years. Korean J. Gastroenterol. 2014;63:299–307.
10. Shenoy S, Shenoy S, et al. Clinicomicrobiological analysis of patients with cholangitis. Indian J Med Microbiol. 2014;32:157.
11. Goo JC, Seong MH, et al. Extended Spectrum‐β‐Lactamase or Carbapenemase Producing bacteria isolated from patients with acute cholangitis. Clin Endosc. 2012;45:155–60.
12. Kiriyama S, Kozaka K, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25:17–30.
13. Goldstein EJ, Solomkin JS, et al. Clinical efficacy and correlation of clinical outcomes with In Vitro susceptibility for anaerobic bacteria in patients with complicated intra‐abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53:1074–80.
14. Buckman SA, Mazuski JE. Review of the Tokyo Guidelines 2018: Antimicrobial Therapy for Acute Cholangitis and Cholecystitis. JAMA Surg. 2019;154(9):873–874
15. Tanaka A, Takada T, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:59–67.
16. Yoshida M, Takada T, et al. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:83–90.
17. Rhodes A, Evans LE, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–77.
18. Solomkin JS, Mazuski JE, et al. Diagnosis and management of complicated Intra‐abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64.
19. Gomi H, Solomkin JS, et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20:60–70.
20. Pisano, M., Allievi, N., et al. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg 15, 61. 2020. https://doi.org/10.1186/s13017-020-00336-x